DekaBank Deutsche Girozentrale Has $198.41 Million Holdings in Amgen Inc. $AMGN

Key Points

• DekaBank Deutsche Girozentrale reduced its holdings in Amgen Inc. by 7.3%, ending the second quarter with 711,647 shares valued at approximately $198.41 million.
• Amgen Inc. reported strong quarterly earnings, with earnings per share of $6.02 beating estimates by $0.74 and revenues of $9.18 billion, exceeding analyst expectations.
• The company announced a quarterly dividend of $2.38 per share, contributing to an annualized dividend yield of 3.1% and a payout ratio of 77.84%.

DekaBank Deutsche Girozentrale lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 7.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 711,647 shares of the medical research company's stock after selling 56,296 shares during the quarter. DekaBank Deutsche Girozentrale owned approximately 0.13% of Amgen worth $198,408,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Wealth Preservation Advisors LLC acquired a new position in Amgen during the first quarter worth approximately $25,000. First Pacific Financial increased its position in Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock worth $28,000 after buying an additional 67 shares during the last quarter. CBIZ Investment Advisory Services LLC increased its position in Amgen by 1,214.3% during the first quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company's stock worth $29,000 after buying an additional 85 shares during the last quarter. Activest Wealth Management increased its position in Amgen by 3,433.3% during the first quarter. Activest Wealth Management now owns 106 shares of the medical research company's stock worth $33,000 after buying an additional 103 shares during the last quarter. Finally, Nova Wealth Management Inc. increased its position in Amgen by 12,200.0% during the first quarter. Nova Wealth Management Inc. now owns 123 shares of the medical research company's stock worth $38,000 after buying an additional 122 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Trading Up 1.5%

Shares of AMGN stock opened at $303.33 on Tuesday. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The stock has a market cap of $163.30 billion, a P/E ratio of 24.80, a price-to-earnings-growth ratio of 2.64 and a beta of 0.49. The stock has a 50 day simple moving average of $287.51 and a 200 day simple moving average of $287.05. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $335.88.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.28 by $0.74. The business had revenue of $9.18 billion during the quarter, compared to analysts' expectations of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company posted $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were paid a dividend of $2.38 per share. The ex-dividend date was Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.1%. Amgen's dividend payout ratio is presently 77.84%.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the company's stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. This represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.69% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on AMGN shares. Wall Street Zen upgraded Amgen from a "hold" rating to a "buy" rating in a report on Sunday. Citigroup boosted their price objective on Amgen from $310.00 to $315.00 and gave the stock a "neutral" rating in a report on Wednesday, September 24th. Morgan Stanley boosted their price objective on Amgen from $330.00 to $333.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Piper Sandler boosted their price objective on Amgen from $328.00 to $342.00 and gave the stock an "overweight" rating in a report on Monday, August 25th. Finally, Bank of America boosted their price objective on Amgen from $261.00 to $272.00 and gave the stock an "underperform" rating in a report on Friday, September 26th. Six investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $300.94.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.